Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 12/2013

01-08-2013 | Therapy in Practice

Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure

Authors: Christoph Schroeder, Jens Jordan, Horacio Kaufmann

Published in: Drugs | Issue 12/2013

Login to get access

Abstract

The maintenance of blood pressure in the upright position requires intact autonomic cardiovascular reflexes. Diseases that affect the sympathetic innervation of the cardiovascular system result in a sustained fall in blood pressure upon standing (i.e., neurogenic orthostatic hypotension) that can impair the blood supply to the brain and other organs and cause considerable morbidity and mortality. Here we review treatment options for neurogenic orthostatic hypotension and include an algorithm for its management that emphasizes the importance of non-pharmacologic measures and provides guidance on pharmacologic treatment options.
Literature
1.
Smit AA, Halliwill JR, Low PA, Wieling W. Pathophysiological basis of orthostatic hypotension in autonomic failure. J Physiol. 1999;519(Pt 1):1–10.PubMed
2.
Matzen S, Perko G, Groth S, Friedman DB, Secher NH. Blood volume distribution during head-up tilt induced central hypovolaemia in man. Clin Physiol. 1991;11(5):411–22.PubMed
3.
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72.PubMed
4.
Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930–6.PubMed
5.
Masaki KH, Schatz IJ, Burchfiel CM, Sharp DS, Chiu D, Foley D, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation. 1998;98(21):2290–5.PubMed
6.
Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 2006;114(7):630–6.PubMed
7.
Ganjehei L, Massumi A, Razavi M, Wilson JM. Orthostatic hypotension as a manifestation of vitamin B12 deficiency. Tex Heart Inst J. 2012;39(5):722–3.PubMed
8.
Girard P, Lebrun C, Peyrade F, Brunetto JL, Chatel M. Orthostatic hypotension revealing vitamin B12 deficiency. Rev Neurol (Paris). 1998;154(4):342–4.
9.
Moore A, Ryan J, Watts M, Pillay I, Clinch D, Lyons D. Orthostatic tolerance in older patients with vitamin B12 deficiency before and after vitamin B12 replacement. Clin Auton Res. 2004;14(2):67–71.PubMed
10.
Graber JJ, Sherman FT, Kaufmann H, Kolodny EH, Sathe S. Vitamin B12-responsive severe leukoencephalopathy and autonomic dysfunction in a patient with “normal” serum B12 levels. J Neurol Neurosurg Psychiatry. 2010;81(12):1369–71.PubMed
11.
Vernino S. Autoimmune and paraneoplastic channelopathies. Neurotherapeutics. 2007;4(2):305–14.PubMed
12.
Schroeder C, Vernino S, Birkenfeld AL, Tank J, Heusser K, Lipp A, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. 2005;353(15):1585–90.PubMed
13.
Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. Epub 2012 Nov 20.
14.
Robertson D. The pathophysiology and diagnosis of orthostatic hypotension. Clin Auton Res. 2008;18(Suppl. 1):2–7.PubMed
15.
Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139–46.PubMed
16.
Kollensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010;25(15):2604–12.PubMed
17.
Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12(3):264–74.PubMed
18.
Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol. 2003;23(4):351–63.PubMed
19.
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996;46(5):1470.
20.
Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(5):584–9.PubMed
21.
Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002;72(6):721–5.PubMed
22.
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17(10):724–9.PubMed
23.
Thaisetthawatkul P, Boeve BF, Benarroch EE, Sandroni P, Ferman TJ, Petersen R, et al. Autonomic dysfunction in dementia with Lewy bodies. Neurology. 2004;62(10):1804–9.PubMed
24.
Sonnesyn H, Nilsen DW, Rongve A, Nore S, Ballard C, Tysnes OB, et al. High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord. 2009;28(4):307–13.PubMed
25.
Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615–24.PubMed
26.
Freeman R. Autonomic peripheral neuropathy. Lancet. 2005;365(9466):1259–70.PubMed
27.
Low PA. Prevalence of orthostatic hypotension. Clin Auton Res. 2008;18(Suppl. 1):8–13.PubMed
28.
Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30(2):173–8.PubMed
29.
Barochiner J, Alfie J, Aparicio L, Rada M, Morales M, Cuffaro P, et al. Orthostatic hypotension in treated hypertensive patients. Rom J Intern Med. 2012;50(3):203–9.PubMed
30.
Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26(5):381–94.PubMed
31.
Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol. 2008;23(Suppl. 1):3–14.PubMed
32.
Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med. 2010;77(5):298–306.PubMed
33.
Podoleanu C, Maggi R, Brignole M, Croci F, Incze A, Solano A, et al. Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol. 2006;48(7):1425–32.PubMed
34.
Tutaj M, Marthol H, Berlin D, Brown CM, Axelrod FB, Hilz MJ. Effect of physical countermaneuvers on orthostatic hypotension in familial dysautonomia. J Neurol. 2006;253(1):65–72.PubMed
35.
ten Harkel AD, van Lieshout JJ, Wieling W. Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin Sci (Lond). 1994;87(5):553–8.
36.
Bouvette CM, McPhee BR, Opfer-Gehrking TL, Low PA. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc. 1996;71(9):847–53.PubMed
37.
Freeman R. Treatment of orthostatic hypotension. Semin Neurol. 2003;23(4):435–42.PubMed
38.
Jordan J, Biaggioni I. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens (Greenwich). 2002;4(2):139–45.
39.
Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000;355(9205):725–6.PubMed
40.
Kronenberg MW, Forman MB, Onrot J, Robertson D. Enhanced left ventricular contractility in autonomic failure: assessment using pressure–volume relations. J Am Coll Cardiol. 1990;15(6):1334–42.PubMed
41.
MacLean AR, Allen BV. Orthostatic hypotension and orthostatic tachycardia: treatment with the “head-up” bed. JAMA. 1940;115(25):2162–7.
42.
ten Harkel AD, van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med. 1992;232(2):139–45.PubMed
43.
Fan CW, Gasparro D, Crowley V, Cunningham CJ. Acute haemodynamic response to sleeping head-up at 6 inches in older inpatients. Clin Auton Res. 2009;19(1):51–7.PubMed
44.
Arnold AC, Biaggioni I. Management approaches to hypertension in autonomic failure. Curr Opin Nephrol Hypertens. 2012;21(5):481–5.PubMed
45.
Shannon JR, Diedrich A, Biaggioni I, Tank J, Robertson RM, Robertson D, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med. 2002;112(5):355–60.PubMed
46.
Deguchi K, Ikeda K, Sasaki I, Shimamura M, Urai Y, Tsukaguchi M, et al. Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy. J Neurol. 2007;254(6):735–40.PubMed
47.
Humm AM, Mason LM, Mathias CJ. Effects of water drinking on cardiovascular responses to supine exercise and on orthostatic hypotension after exercise in pure autonomic failure. J Neurol Neurosurg Psychiatry. 2008;79(10):1160–4.PubMed
48.
May M, Jordan J. The osmopressor response to water drinking. Am J Physiol Regul Integr Comp Physiol. 2011;300(1):R40–6.PubMed
49.
Raj SR, Biaggioni I, Black BK, Rali A, Jordan J, Taneja I, et al. Sodium paradoxically reduces the gastropressor response in patients with orthostatic hypotension. Hypertension. 2006;48(2):329–34.PubMed
50.
Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation. 2000;101(5):504–9.PubMed
51.
Z’Graggen WJ, Hess CW, Humm AM. Acute fluid ingestion in the treatment of orthostatic intolerance—important implications for daily practice. Eur J Neurol. 2010;17(11):1370–6.PubMed
52.
Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41(5):587–94.PubMed
53.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl. 3):S42–80.PubMed
54.
Gibbons CH, Raj SR. A meta-analysis of pharmacologic treatments of orthostatic hypotension [abstract]. Clin Auton Res. 2012;22(5):231–2.
55.
Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105(2):116–24.PubMed
56.
Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–51.PubMed
57.
Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48.PubMed
58.
Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120–4.PubMed
59.
Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604–10.PubMed
60.
Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab. 1998;83(2):339–43.PubMed
61.
Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology. 1988;38(6):951–6.PubMed
62.
Steinbach K, Weidinger P. Effect of midodrin on orthostasis. Wien Klin Wochenschr. 1973;85(38):621–4.PubMed
63.
Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A, Fealey RD. Pharmacodynamics of midodrine, an antihypotensive agent. Clin Pharmacol Ther. 1986;39(5):586–91.PubMed
64.
Schirger A, Sheps SG, Thomas JE, Fealey RD. Midodrine: a new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome. Mayo Clin Proc. 1981;56(7):429–33.PubMed
65.
Cruz DN. Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. Expert Opin Pharmacother. 2000;1(4):835–40.PubMed
66.
Pohl K, Kriech W. Therapy of orthostatic disorders of cardiovascular regulation: placebo controlled double-blind study with oxilofrine. Fortschr Med. 1991;109(33):685–8.PubMed
67.
Freistuhler M, Passenberg P, Burger M. The Shy-Drager syndrome. Dtsch Med Wochenschr. 1992;117(30):1146–8.PubMed
68.
Gemeinhardt S, Schardt F, Polzien P. Abnormalities of hypotonic orthostatic regulation: cardiovascular effects of dihydroergotamine, etilefrine and their combination [author’s transl]. Dtsch Med Wochenschr. 1981;106(35):1095–9.PubMed
69.
Broadley KJ. The vascular effects of trace amines and amphetamines. Pharmacol Ther. 2010;125(3):363–75.PubMed
70.
Robertson D, Hollister AS, Carey EL, Tung CS, Goldberg MR, Robertson RM. Increased vascular beta2-adrenoceptor responsiveness in autonomic dysfunction. J Am Coll Cardiol. 1984;3(3):850–6.PubMed
71.
Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826–32.PubMed
72.
Mathias CJ. l-Dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res. 2008;18(Suppl. 1):25–9.PubMed
73.
Kaufmann H. l-Dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008;18(Suppl. 1):19–24.PubMed
74.
Man in ‘t Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet. 1987;2(8569):1172–5.PubMed
75.
Mathias CJ, Bannister RB, Cortelli P, Heslop K, Polak JM, Raimbach S, et al. Clinical, autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta hydroxylase. Q J Med. 1990;75(278):617–33.PubMed
76.
Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, Thompson JG Jr, et al. Isolated failure of autonomic noradrenergic neurotransmission: evidence for impaired beta-hydroxylation of dopamine. N Engl J Med. 1986;314(23):1494–7.PubMed
77.
Garland EM, Raj SR, Demartinis N, Robertson D. Case report: marathon runner with severe autonomic failure. Lancet. 2005;366(Suppl. 1):S13.PubMed
78.
Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, et al. l-Threo-dihydroxyphenylserine (l-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11(4):235–42.PubMed
79.
Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724–8.PubMed
80.
Mathias CJ, Senard JM, Cortelli P. A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy or Parkinson’s disease [abstract]. Clin Auton Res. 2007;17(272).
81.
Kaufmann H, Freeman R, Biaggioni I, Low PA, Pedder S, Hewitt A, et al. Treatment of neurogenic orthostatic hypotension with droxidopa: results from a multi-center, double-blind, randomized, placebo-controlled, parallel group, induction design study [abstract]. Neurology. 2012;78(Suppl. 1):4–22.
82.
Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74(9):1294–8.PubMed
83.
Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513–8.PubMed
84.
Sandroni P, Opfer-Gehrking TL, Singer W, Low PA. Pyridostigmine for treatment of neurogenic orthostatic hypotension [correction of hypertension]—a follow-up survey study. Clin Auton Res. 2005;15(1):51–3.PubMed
85.
Shibao C, Okamoto LE, Gamboa A, Yu C, Diedrich A, Raj SR, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847–51.PubMed
86.
Grossman E, Rea RF, Hoffman A, Goldstein DS. Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am J Physiol. 1991;260(1 Pt 2):R142–7.PubMed
87.
Senard JM, Rascol O, Durrieu G, Tran MA, Berlan M, Rascol A, et al. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson disease or multiple system atrophy. Clin Neuropharmacol. 1993;16(1):70–6.PubMed
88.
Sharabi Y, Eldadah B, Li ST, Dendi R, Pechnik S, Holmes C, et al. Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol. 2006;29(3):97–105.PubMed
89.
Kochar MS, Itskovitz HD. Treatment of idiopathic orthostatic hypotension (Shy-Drager syndrome) with indomethacin. Lancet. 1978;1(8072):1011–4.PubMed
90.
Abate G, Polimeni RM, Cuccurullo F, Puddu P, Lenzi S. Effects of indomethacin on postural hypotension in Parkinsonism. Br Med J. 1979;2(6203):1466–8.PubMed
91.
Watt SJ, Tooke JE, Perkins CM, Lee MR. The treatment of idiopathic orthostatic hypotension: a combined fludrocortisone and flurbiprofen regime. Q J Med. 1981;50(198):205–12.PubMed
92.
Aellig WH. Direct effects of vasoactive substances on superficial human veins in vivo. Int Angiol. 1985;4(2):235–42.PubMed
93.
Muth HH, Jansen W. Dihydroergot plus in the long-term therapy of orthostatic hypotonic dysregulation in older patients. Fortschr Med. 1980;98(40):1571–4.PubMed
94.
Lang E. Orthostatic hypotension in the aged. Cardiology. 1976;61(Suppl. 1):225–35.PubMed
95.
Thulesius O, Berlin E. Dihydroergotamine therapy in orthostatic hypotension due to psychotropic drugs. Int J Clin Pharmacol Ther Toxicol. 1986;24(9):465–7.PubMed
96.
Mannelli M, Pupilli C, Fabbri G, Musante R, De Feo ML, Franchi F, et al. Endogenous dopamine (DA) and DA2 receptors: a mechanism limiting excessive sympathetic-adrenal discharge in humans. J Clin Endocrinol Metab. 1988;66(3):626–31.PubMed
97.
Magnifico F, Pierangeli G, Barletta G, Candela C, Bonavina G, Contin M, et al. The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11(3):163–8.PubMed
98.
Destee A, Leys D, Delisse B, Warot P. Orthostatic hypotension due to diabetic autonomic neuropathy? Treatment with domperidone. Arch Neurol. 1987;44(1):11.PubMed
99.
Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22(11):1543–9.PubMed
100.
Lopes de Faria SR, Zanella MT, Andriolo A, Ribeiro AB, Chacra AR. Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin Pharmacol Ther. 1988;44(6):670–4.PubMed
101.
Montastruc JL, Chamontin B, Senard JM, Rascol A. Domperidone in the management of orthostatic hypotension. Clin Neuropharmacol. 1985;8(2):191–2.PubMed
102.
Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martinez-Bengoechea MJ, Garcia-Monco JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson’s disease. Am J Health Syst Pharm. 2008;65(5):414–9.PubMed
103.
Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5(3):257–62.PubMed
104.
van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003–14.PubMed
105.
Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881–8.PubMed
106.
Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 2002;105(3):347–53.PubMed
107.
Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, et al. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation. 2003;107(23):2949–54.PubMed
108.
Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47–53.PubMed
109.
Okamoto LE, Shibao C, Gamboa A, Choi L, Diedrich A, Raj SR, et al. Synergistic effect of norepinephrine transporter blockade and alpha-2 antagonism on blood pressure in autonomic failure. Hypertension. 2012;59(3):650–6.PubMed
110.
Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979;301(2):68–73.PubMed
111.
Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83(6):1849–65.PubMed
112.
van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res. 2000;10(1):35–42.PubMed
113.
Norcliffe-Kaufmann L, Axelrod FB, Kaufmann H. Developmental abnormalities, blood pressure variability and renal disease in Riley Day syndrome. J Hum Hypertens. 2013;27(1):51–5.PubMed
114.
Biaggioni I, Robertson D, Krantz S, Jones M, Haile V. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med. 1994;121(3):181–6.PubMed
115.
Winkler AS, Marsden J, Parton M, Watkins PJ, Chaudhuri KR. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord. 2001;16(2):233–9.PubMed
116.
Winkler AS, Landau S, Watkins P, Chaudhuri KR. Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. Clin Auton Res. 2002;12(3):203–6.PubMed
117.
Rao SV, Stamler JS. Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin Auton Res. 2002;12(3):141–3.PubMed
118.
Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med. 1993;329(9):611–5.PubMed
119.
Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res. 1995;5(4):211–3.PubMed
120.
Winkler AS, Landau S, Watkins PJ. Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with autonomic neuropathy: a case study of four patients. Diabetes Care. 2001;24(6):1121–3.PubMed
121.
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.PubMed
122.
Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol. 1994;21(1):88–94.PubMed
123.
Hoeldtke RD, Bryner KD, Hoeldtke ME, Hobbs G. Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR. Clin Auton Res. 2007;17(6):334–40.PubMed
124.
Bordet R, Benhadjali J, Destee A, Belabbas A, Libersa C. Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration. Clin Neuropharmacol. 1995;18(1):83–9.PubMed
125.
Lamarre-Cliche M, Cusson J. Octreotide for orthostatic hypotension. Can J Clin Pharmacol. 1999;6(4):213–5.PubMed
126.
Smith GD, Alam M, Watson LP, Mathias CJ. Effect of the somatostatin analogue, octreotide, on exercise-induced hypotension in human subjects with chronic sympathetic failure. Clin Sci (Lond). 1995;89(4):367–73.
127.
Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology. 1992;42(3 Pt 1):590–3.PubMed
128.
Ozawa T, Oyanagi K, Tanaka H, Horikawa Y, Takahashi H, Morita T, et al. Suprachiasmatic nucleus in a patient with multiple system atrophy with abnormal circadian rhythm of arginine-vasopressin secretion into plasma. J Neurol Sci. 1998;154(1):116–21.PubMed
129.
Manning M, Sawyer WH. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J Recept Res. 1993;13(1–4):195–214.PubMed
130.
Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord. 1995;10(3):337–40.PubMed
131.
Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed). 1986;293(6543):353–4.
132.
Jordan J, Shannon JR, Pohar B, Paranjape SY, Robertson D, Robertson RM, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol. 1999;10(1):35–42.PubMed
133.
Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, et al. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension. 2006;47(3):522–6.PubMed
134.
Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension. 1997;30(5):1062–7.PubMed
135.
Polinsky RJ, Samaras GM, Kopin IJ. Sympathetic neural prosthesis for managing orthostatic hypotension. Lancet. 1983;1(8330):901–4.PubMed
136.
Goldstein DS, Sewell L, Holmes C, Pechnik S, Diedrich A, Robertson D. Temporary elimination of orthostatic hypotension by norepinephrine infusion. Clin Auton Res. 2012;22(6):303–6.PubMed
137.
Sato T, Kawada T, Shishido T, Sugimachi M, Alexander J Jr, Sunagawa K. Novel therapeutic strategy against central baroreflex failure: a bionic baroreflex system. Circulation. 1999;100(3):299–304.PubMed
Metadata
Title
Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure
Authors
Christoph Schroeder
Jens Jordan
Horacio Kaufmann
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 12/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0097-0

Other articles of this Issue 12/2013

Drugs 12/2013 Go to the issue

Systematic Review

Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review

Review Article

Extra-Esophageal Manifestations of Gastroesophageal Reflux Disease: Diagnosis and Treatment

Leading Article

Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies

Adis Drug Evaluation

Recombinant Trivalent Influenza Vaccine (Flublok®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults

R&D Insight Report

Acotiamide: First Global Approval

Adis Drug Evaluation

Sumatriptan/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine